

Summary of minutes of EUCAST Steering Committee Meeting Madrid, Spain, 29-30 January 2007

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Canton	RC	Clinical Data Co-ordinator	Spain
Dr Christian Giske	CG	SRGA	Sweden
Dr Fred Goldstein	FG	SFM	France
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Dr Martin Steinbakk	MS	NWGA	Norway
Prof Pietro Varaldo	PV	EUCAST	Italy

Apologies

Prof Waleria Hryniewicz	WH	EUCAST	Poland
Prof Inga Odenholt	IO	SRGA	Sweden

In attendance for item 13

Dr J. Peter Donnelly	PD	University Medical Centre St Radboud, Nijmegen, The Netherlands
Dr Juan-Luis Rodriguez-Tudela	JR	National Center for Microbiology, Majadahonda, Spain
Dr Manuel Cuenca-Estrella	ME	National Center for Microbiology, Majadahonda, Spain
Dr Cornelia Lass-Flörl	CF	Division of Hygiene and Microbiology, Innesbruck Medical University, Austria
Dr Maiken Cavling Arendrup	MA	Statens Serum Institut, Copenhagen, Denmark

1	Chairman's welcome
2	Minutes of meeting of 20-21 November 2006 With minor corrections the minutes were accepted as a correct record.
3	<p>Matters arising from minutes of 20-21 November 2006 Content of the clinical data section for older agents was agreed.</p> <p>Most declarations of interest have been returned.</p> <p>For <i>S. pneumoniae</i> with piperacillin-tazobactam susceptibility should be inferred from the penicillin susceptibility.</p> <p>Developments of the wild type website are in progress.</p> <p>Documents related to new quinolone breakpoints have been updated.</p> <p>Technical notes and rationale documents for aminoglycosides, carbapenems, glycopeptides, penicillins, fluoroquinolones, fluconazole, macrolides and miscellaneous agents are progressing and are at various stages of development.</p> <p>For trimethoprim with enterococci evidence on clinical validity is not available.</p>
4	<p>CLSI Relationships between CLSI and FDA are still to be clarified.</p> <p>Penicillin breakpoints for pneumococci will be reviewed at the meeting in June and revised CLSI cephalosporin breakpoints for Enterobacteriaceae will be developed.</p>
5	<p>Ciprofloxacin rationale document The document was update as a model for others.</p>

6	New glycopeptide A preliminary presentation was given by the company.
7	New quinolone The company response to EUCAST proposals was reviewed.
8	New quinolone meeting with the company The company response to EUCAST proposals was discussed and breakpoints finalised.
9	Miscellaneous agents Dosage and current breakpoint data were updated.
10	Expert rules sub-committee The first draft was now completed and will be sent to National Committees for comment.
11	EMEA Proposed changes to the EMEA-EUCAST SOP were agreed.
12	New drugs Current status was reviewed.
13	Joint meeting with the AFST subcommittee Proposals for future activity were discussed. Problems with different methodologies were highlighted. The fluconazole rationale document was reviewed.
14	Macrolides Draft breakpoints were reviewed and updated. The breakpoints will be sent for wider consultation.
15	ISO/CEN The document on assessment of in-vitro methods is about to go for final voting.
16	Miscellaneous agents National data have been tabulated. Breakpoints will be discussed at the next meeting.
17	Penicillins Draft breakpoints were reviewed and updated. The breakpoints will be sent for wider consultation.
18	Any other business Implementation of EUCAST breakpoints in disc diffusion methods is done for BSAC, SRGA and SFM methods.
19	Next meetings 3-4 April 2007, Munich; 14-15 June 2007, Copenhagen; 6-7 September 2007, Berlin; 19-20 November 2007, Paris

Ratified summary of minutes of meeting 29-30 January 2007. Prepared by DB, GK and RC